Resource Logo
BBC News

Bavarian Nordic Vaccine Programs Progressing as Planned:


WASHINGTON D.C., November 6 /PRNewswire-FirstCall/ -- In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

IMVAMUNE(R) next-generation smallpox vaccine

Clinical development of IMVAMUNE(R) as a safe smallpox vaccine is proceeding as planned. Phase III studies with IMVAMUNE(R) in healthy subjects are expected to be initiated in 2008.


Copyright © 2007 -BBC News, Publisher. All rights reserved to BBC Reproduction of this article (other than one copy for personal reference) must be clered through the BBC.

Information in this article was accurate in November 6, 2007. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.